Abstract
A new series of 7-fluoro-6-(4-methyl-1-piperazinyl)-2-(thiosubstituted)-4(3H)-quinazolinones was synthesized as potential antitumor agents by multi-step synthesis starting with the commercially available 3-chloro-4-fluoroaniline. The most promising candidate, 7-fluoro-6-(4- methyl-1-thyl-1-piperazinyl)- 2-thioethyl-4(3H)-quinazolinone (5a), was screened in 60 human cancer cells by NCI.
Keywords: Quinazolinone derivatives, piperazine derivatives, anticancer activity
Letters in Organic Chemistry
Title: Synthesis and In-Vitro Antitumor Activity of Selected 7-Fluoro-6-(4-methyl-1-piperazinyl)-2-(thiosubstituted)-4(3H)-quinazolinones
Volume: 7 Issue: 5
Author(s): Raid J. Abdel-Jalil, Ehab Al-Momani, Lubna Tahtamooni, H.-Juergen Machulla and Wolfgang Voelter
Affiliation:
Keywords: Quinazolinone derivatives, piperazine derivatives, anticancer activity
Abstract: A new series of 7-fluoro-6-(4-methyl-1-piperazinyl)-2-(thiosubstituted)-4(3H)-quinazolinones was synthesized as potential antitumor agents by multi-step synthesis starting with the commercially available 3-chloro-4-fluoroaniline. The most promising candidate, 7-fluoro-6-(4- methyl-1-thyl-1-piperazinyl)- 2-thioethyl-4(3H)-quinazolinone (5a), was screened in 60 human cancer cells by NCI.
Export Options
About this article
Cite this article as:
J. Abdel-Jalil Raid, Al-Momani Ehab, Tahtamooni Lubna, Machulla H.-Juergen and Voelter Wolfgang, Synthesis and In-Vitro Antitumor Activity of Selected 7-Fluoro-6-(4-methyl-1-piperazinyl)-2-(thiosubstituted)-4(3H)-quinazolinones, Letters in Organic Chemistry 2010; 7 (5) . https://dx.doi.org/10.2174/157017810791514751
DOI https://dx.doi.org/10.2174/157017810791514751 |
Print ISSN 1570-1786 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6255 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Strategies that Target Tight Junctions for Enhanced Drug Delivery
Current Pharmaceutical Design Dichotomous Life of DNA Binding High Mobility Group Box1 Protein in Human Health and Disease
Current Protein & Peptide Science Angiogenesis Inhibitors and Vascular Disrupting Agents in Non-Small Cell Lung Cancer
Current Medicinal Chemistry Structure and Ligand Based Drug Design Strategies in the Development of Novel 5- LOX Inhibitors
Current Medicinal Chemistry Chronic Diseases and COVID-19: A Review
Endocrine, Metabolic & Immune Disorders - Drug Targets Volatile Organic Compounds Trapping from Gaseous Samples on the Basis of Co-Liquefaction with Organic Solvent for Gas Chromatographic Analysis
Current Analytical Chemistry Therapeutic Boosting of the Immune Response: Turning to CD14 for Help
Current Pharmaceutical Biotechnology Cancer-Related Fatigue: Still an Enigma to be Solved Quickly
Reviews on Recent Clinical Trials Small Molecule Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors in Non Small Cell Lung Cancer Treatment
Current Cancer Therapy Reviews Patent Selections
Recent Patents on Biomarkers Cisplatin Is a DNA-Damaging Antitumour Compound Triggering Multifactorial Biochemical Responses in Cancer Cells: Importance of Apoptotic Pathways
Current Medicinal Chemistry - Anti-Cancer Agents Targeted Delivery for Neurodegenerative Disorders Using Gene Therapy Vectors: Gene Next Therapeutic Goals
Current Gene Therapy Current Status and Future Perspectives of PI3K and mTOR Inhibitor as Anticancer Drugs in Breast Cancer
Current Cancer Drug Targets Validation of Self-Report of Chest X-Ray Exam at a Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial Center
Reviews on Recent Clinical Trials The Changing Face of HIV/AIDS in Treated Patients
Current HIV Research Novel Agents Targeting Crucial Signalling Pathways in Head and Neck Squamous Cell Carcinoma, HNSCC - Preclinical Development and Data from Clinical Trials
Current Proteomics Editorial (Thematic Issue: The Lung and Winding Road: Twists and Turns on the Way to Personalized NSCLC Therapy)
Current Pharmaceutical Design Thalidomide Derived Immunomodulatory Drugs (IMiDs) as Potential Therapeutic Agents
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Functional Nanoplatforms for Enhancement of Chemotherapeutic Index
Anti-Cancer Agents in Medicinal Chemistry The Role of COX-2 in Oral Cancer Development, and Chemoprevention/ Treatment of Oral Cancer by Selective COX-2 Inhibitors
Current Pharmaceutical Design